Skip to main content
OpenTrials
Completed

NCT Number: NCT02712489

A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial

A roll-over observational study (ISS T-003 EF-UP) is being conducted to extend the follow-up of the volunteers of the ISS T-003 trial in order to evaluate the persistence of vaccine immunogenicity as well as of the immunological and virological effects induced by the therapeutic immunization with Tat.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Matsontso Mathebula Mecru Clinical Research Unit, Sefako Makgatho, Health Sciences University,

Medunsa, Gauteng, 0204, South Africa

About this study

An open label, non-interventional study roll-over study (ISS T-003 EF-UP) is being conducted to follow-up the persistence of vaccine humoral responses as well as of the immunological and virological effects induced by the therapeutic immunization with Tat.To this aim volunteers of the ISS T-003 study are included in one year study, with visits at weeks 0 and 24 and 54.

To assess the anti-Tat humoral immune response by the determination and titration of IgM, IgG and IgA anti-Tat antibodies (primary endpoint) and to evaluate CD4+ T cell counts and HIV-1 plasma viraemia (as secondary endpoint).

In addition, depending on the availability of residual specimens (PBMC, serum and plasma), further laboratory tests (i.e. HIV DNA copies in blood) to investigate in-depth the immunological and virological profile of the volunteers is being performed.

Physical examination is being performed to monitor the clinical status of the volunteers and to record the appearance of clinical signs and symptoms of disease progression as well as AIDS-defining events, data or records related to ARV treatment compliance. Pregnancy onset for female participants will also be recorded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • previous participation in the ISS T-003 trial without withdrawal of consent;
  • availability to participate in the extended follow-up study;
  • signed informed consent.

Exclusion criteria

  • The absence of any of the above criteria will exclude the participants from the study

Treatment and study plan

No intervention

Other

Primary outcomes

  1. Presence of specific anti-Tat humoral immune response

    Time frame: Through study completion, an average of 1 year

    anti-Tat IgM, IgG, IgA antibodies

Secondary outcomes

  1. CD4+ T cell counts

    Time frame: Through study completion, an average of 1 year

  2. HIV-1 RNA Viral Load

    Time frame: Through study completion, an average of 1 year

Sponsors and collaborators

Lead sponsor

Barbara Ensoli, MD, PhD

Other

Collaborators

  • Italian Ministry of Foreign Affairs - General Direction for Cooperation and Development

Registry information

Official study title

A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP)

Acronym: ISST-003EF-UP

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Mar 18, 2016
Registry last updated
Dec 29, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.